These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 20201946

  • 1. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S, Hansson U, Olsson M, Torén L, Bergström A, Nilsson-Ehle H, Andersson PO.
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [Abstract] [Full Text] [Related]

  • 2. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY.
    Ann Hematol; 2010 Oct 20; 89(10):985-91. PubMed ID: 20428871
    [Abstract] [Full Text] [Related]

  • 4. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ.
    J Clin Oncol; 2009 Nov 20; 27(33):5573-9. PubMed ID: 19786664
    [Abstract] [Full Text] [Related]

  • 5. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 6. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M.
    Ann Hematol; 2011 Feb 10; 90(2):185-92. PubMed ID: 20809421
    [Abstract] [Full Text] [Related]

  • 7. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 8. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May 01; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 9. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN.
    Zhonghua Zhong Liu Za Zhi; 2005 Mar 01; 27(3):174-6. PubMed ID: 15946571
    [Abstract] [Full Text] [Related]

  • 10. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Aug 01; 23(22):5027-33. PubMed ID: 15955905
    [Abstract] [Full Text] [Related]

  • 11. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD.
    Am J Clin Pathol; 2011 Jan 01; 135(1):54-61. PubMed ID: 21173124
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ.
    J Pathol; 2006 Apr 01; 208(5):714-23. PubMed ID: 16400625
    [Abstract] [Full Text] [Related]

  • 13. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study.
    Ann Hematol; 2004 Jul 01; 83(7):414-9. PubMed ID: 15085385
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study.
    Clin Cancer Res; 2003 Feb 01; 9(2):722-8. PubMed ID: 12576441
    [Abstract] [Full Text] [Related]

  • 15. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J.
    Ann Hematol; 2006 Sep 01; 85(9):597-603. PubMed ID: 16830142
    [Abstract] [Full Text] [Related]

  • 16. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN.
    Am J Hematol; 2009 Feb 01; 84(2):93-7. PubMed ID: 19123458
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB.
    Am J Hematol; 2003 Jun 01; 73(2):101-7. PubMed ID: 12749011
    [Abstract] [Full Text] [Related]

  • 18. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 01; 30(3):200-2. PubMed ID: 18756936
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T.
    Histopathology; 2013 Dec 01; 63(6):788-801. PubMed ID: 24117687
    [Abstract] [Full Text] [Related]

  • 20. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 01; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.